UPC
Universe Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CN
$3.76
−4.33%Year over year
Reported trailing growth
- Revenue
- -8.0%
- EBITDA
- —
- EBIT
- +75.7%
- EPS
- +98.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -23.7%
- EBITDA
- +60.3%
- EBIT
- +63.6%
- Net income
- +57.9%
- EPS
- +26.5%
- Free cash flow
- +45.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026